NCT05984238View on ClinicalTrials.gov

A Trial to Evaluate Safety, Feasibility and Efficacy of the ReCET Procedure (EMINENT-2)

NARecruitingINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

August 3, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

October 31, 2025

Conditions

Diabetes Mellitus, Type 2

Interventions

DEVICE

ReCET

Investigational product.

DRUG

Semaglutide, 1.0 mg/mL

Already registered medicine for type 2 diabetes

OTHER

Sham procedure

The sham control for the ReCET procedure.

Trial Locations (1)

1105 AZ

RECRUITING

Amsterdam UMC, Amsterdam

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Endogenex

UNKNOWN

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER